We have documented that a cellular chaperone protein, FKBP52, when phosphorylated at tyrosine and/or serine/ threonine (Ser/Thr) residues, interacts with the D-sequence in the inverted terminal repeats of the adeno-associated virus 2 (AAV) genome, inhibits the viral second-strand DNA synthesis, and leads to inefficient transgene expression from recombinant AAV vectors in certain cell types. We have also demonstrated that FKBP52 is dephosphorylated at tyrosine residues by T-cell protein tyrosine phosphatase (TC-PTP), and that deliberate overexpression of TC-PTP leads to more efficient viral second-strand DNA synthesis, and increased transgene expression. However, the identity of the putative Ser/Thr protein phosphatase that dephosphorylates FKBP52 at Ser/Thr residues has remained elusive. Using known inhibitors of Ser/Thr phosphatases, we have now identified protein phosphatase 5 (PP5) to be a candidate enzyme.
Adeno-associated virus 2 (AAV), a non-pathogenic human parvovirus, has gained attention as a potentially safe vector for gene transfer and gene therapy. 1, 2 The AAV genome is a single-stranded DNA, 3, 4 which is transcriptionally inactive. Others and we have suggested that viral second-strand DNA synthesis is the rate-limiting step in AAV-mediated transgene expression. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In our previous studies, we have identified that a 52-kDa cellular protein, FKBP52, which binds the immunosuppressant drug, FK506, interacts specifically with the D-sequence within the inverted terminal repeat (ITR) of the AAV genome. FKBP52 is phosphorylated at both tyrosine (Tyr) and serine or threonine (Ser/Thr) residues, and phosphorylated FKBP52 inhibits the viral second-strand DNA synthesis, leading to inefficient transgene expression, [7] [8] [9] [10] [11] [12] [13] 16, 17 and dephosphorylated FKBP52 can no longer bind to the D-sequence, thereby allowing viral second-strand DNA synthesis and, consequently, efficient transgene expression. We have also documented that FKBP52 is dephosphorylated at tyrosine residues by the cellular T-cell protein tyrosine phosphatase (TC-PTP) and increases AAV transduction efficiency in vitro and in vivo. [9] [10] [11] [12] [13] However, the putative cellular Ser/Thr phosphatase that dephosphorylates FKBP52 has remained elusive.
Cells contain a number of Ser/Thr protein phosphatases, and according to the structure of the catalytic domain, protein phosphatases can be classified into Mg 2+ -stimulated protein phosphatase (PPM family), protein-tyrosine phosphatase (PTP family), dual-specificity protein phosphatase and others, such as histone phosphatase, and phosphoserine/phosphothreoninespecific protein phosphatase (PPP family). 18 We focused our efforts on the PPP family primarily because the putative phosphatase that catalyzes dephosphorylation of FKBP52 was expected to be a Ser/Thr phosphatase. PPP has four subfamilies, which are protein phosphatases 1 (PP1), protein phosphatases 2A (PP2A), protein phosphatases 2B (PP2B, calcineurin) and protein phosphatases 5 (PP5). 18, 19 We hypothesized that PP5, a 58-kDa Ser/Thr protein phosphatase, was among the likely candidate as it is ubiquitously expressed in all types of mammalian tissue, with a relatively high level in the brain, 20, 21 and the transduction efficiency of AAV vectors is particularly high in the brain. 22 Furthermore, although PP5 is present in both nuclear and cytoplasmic compartments, its subcellular localization predominates in the nucleus, 19, 23 a site where dephosphorylation of FKBP52 is most likely to occur. And finally, as PP5 contains a C-terminal catalytic domain structurally related to the PP1/PP2A/PP2B family and an N-terminal regulatory domain consisting of three tetratricopeptide repeats (TPRs) that usually mediate protein-protein interaction, 24 it has been demonstrated that PP5 interacts with multiple unrelated target proteins through the TPR domain, [25] [26] [27] [28] [29] [30] [31] and FKBP52 is known to contain a TPR domain. 32, 33 In the current study, we used various known inhibitors of protein Ser/Thr phosphatases to pretreat an established human embryonic kidney cell line 293, in which FKBP52 is present predominantly in the Ser/Thr phosphorylated form. 8, 16 The transduction efficiency of conventional single-stranded AAV (ssAAV) vectors was determined in untreated and pretreated cells. Approximately 3 Â 10 5 293 cells were plated in each well in 12-well plates and incubated at 371C for 12 h. Cells were pretreated with various inhibitors for 2 h and washed once with Iscove's-modified Dulbecco's medium and then either mock-infected, or infected at 371C for 2 h with a multiplicity of infection (MOI) of 500 particles/cell of recombinant AAV enhanced green fluorescent protein (AAV-EGFP) vectors. Forty-eight hours post-infection, the transduction efficiency of AAV was measured by GFP imaging using a Zeiss Axiovert 25 fluorescence microscope (Carl Zeiss Inc., Thornwood, NY, USA). Images from three visual fields of mock-infected and vector-infected cells were analyzed quantitatively by ImageJ analysis software (NIH, Bethesda, MD, USA). Transgene expression was assessed as total area of green fluorescence (pixel 2 ) per visual field. These results are shown in Figure 1 . Consistent with our previous studies, 16, 17 pretreatment with staurosporine, an inhibitor of Ser/Thr kinase, enhanced the transduction efficiency of ssAAV vectors B5-fold. Pretreatment with 100 nM cyclosporine A, which is a highly selective inhibitor of PP2B, and 10 nM calyculin A, which mainly inhibits PP1 and PP2A, had no significant effect. Fostriecin, which inhibits PP2A (half-maximal inhibitory concentration (IC 50 ) 5 nM) 34 at levels 10 000-fold less than required for PP5 inhibition (IC 50 70 mM), 35 also had no influence on ssAAV-mediated transduction at 100 nM concentration. However, 100 nM cantharidin, which is an inhibitor of PP2A (IC 50 40 nM) and PP5 (IC 50 50 nM), and okadaic acid, which is an inhibitor of PP1 (IC 50 10-15 nM), PP2A (IC 50 100 pM) and PP5 (IC 50 7 nM), 36 decreased the transduction efficiency of ssAAV vectors by B40%. These results suggest that inhibitors of PP5, but not inhibitors of PP1, PP2A or PP2B, affect the ssAAV transduction efficiency presumably by inhibiting Ser/ Thr dephosphorylation of FKBP52, which in turn, inhibits the viral second-strand DNA synthesis. Thus, consistent with our hypothesis, PP5 is a possible candidate enzyme that catalyzes Ser/Thr dephosphorylation of FKBP52.
To further confirm the role of PP5 in AAV vectormediated transgene expression, we constructed an eucaryotic expression plasmid, which expresses human PP5 cDNA under the control of the cytomegalovirus immediate-early gene promoter (CMVp). PP5 contains catalytic, regulatory and subcellular targeting functions within a single polypeptide chain, the catalytic domain of PP5 is closely related to the catalytic subunits of PP1, PP2A and PP2B, being 42-43% identical to each in amino-acid sequence. 37 Despite these similarities, PP5 has distinctive biochemical and biological properties owing to its N-terminal TPR domain, which serves both targeting and regulatory functions. Even though removal of the TPR domain leads to a substantial increase in phosphatase activity, [38] [39] [40] the crystal structure of the TPR domain of PP5 reveals a super-helical structure with an amphipathic groove, which provides a site for binding of other TPR domains or unrelated proteins. 24, 41 Therefore, we used the complete cDNA of human PP5, which encodes the TPR and phosphatase domains, and inserted it into the multiple cloning site of pcDNA3.1(À)/Neo vector. 293 cells were stably transfected with this plasmid using the drug, G418. Individual G418-resistant PP5-overexpressing 293 cell colonies were isolated after 4 AAV-mediated gene transfer W Zhao et al weeks of selection and the levels of PP5 were analyzed on Western blots using anti-PP5 antibodies. These results are shown in Figure 2 . The levels of PP5 increased B3-fold following stable transfection with a PP5-overexpressing plasmid (Figure 2a ). Because alterations in cellular growth can affect the AAV transduction efficiency, it was important to determine whether deliberate overexpression of PP5 affected cellular growth, which was evaluated following stable transfection. As can be seen in Figure 2b , stable transfection of 293 cells with pcDNA3.1(À)/PP5-Neo plasmid did not alter cellular growth. Cells grew well, and the growth curves were superimposable to those of control and mock-transfected cells.
The human PP5-overexpressing 293 cells were infected with ssAAV-EGFP vectors at an MOI of 500 particles/ cell. Forty-eight hours post-infection, the cells were visualized under a fluorescence microscope. As can be seen in Figure 2c , compared with control 293 cells, deliberate overexpression of PP5 significantly enhanced ssAAV transduction efficiency. A quantitative analysis of the data (Figure 2d) showed that PP5 overexpression led to B5-fold increase in the AAV transduction efficiency. These results further corroborate our hypothesis that FKBP52 is a substrate for PP5, and that PP5-mediated dephosphorylation of FKBP52 augments the viral second-strand DNA synthesis, and consequently, transgene expression.
Although it was plausible that deliberate overexpression PP5 affected one or more of the several steps that influence AAV-mediated transgene expression, which include viral entry, intracellular trafficking and uncoating, we focused our efforts on viral second-strand AAV DNA synthesis. To this end, we used self-complementary AAV (scAAV) vectors, which contain a double-stranded genome, and thus bypass the requirement for viral second-strand DNA synthesis.
14,15 PP5-overexpressing 293 cells were infected with ssAAV-or scAAV-EGFP vectors at an MOI of 500 particles/cell, and the transduction efficiency was evaluated 48 h post-infection. These results are shown in Figure 3 . As is evident, whereas the transduction efficiency of ssAAV vectors was significantly increased in PP5-overexpressing 293 cells, overexpression of PP5 failed to significantly enhance the transduction efficiency of scAAV vectors under identical conditions. These data further invoke a direct role of PP5 in AAV second-strand DNA synthesis.
We next wished to examine whether PP5 plays a role that affects the interaction between FKBP52 and the D-sequence in the AAV-ITR for which electrophoretic mobility-shift assays (EMSAs) were performed. Wholecell extracts (WCEs) from untransfected 293 cells and those from mock-or pcDNA3.1(À)/PP5-Neo plasmidtransfected cells were prepared according to the method described by Muller. 42 EMSAs were performed as described previously. 7, 8 Briefly, DNA-binding reactions were performed in a volume of 20 ml with 2 mg of poly(dI)-poly(dC), 2 mg of bovine serum albumin and 12% glycerol in 4-(2-hydroxyethyl)-1-piperazineethylsulphonic acid buffer (pH 7.9). Ten micrograms of AAV-mediated gene transfer W Zhao et al protein from each WCE was preincubated for 10 min at 251C followed by the addition of 10 000 c.p.m. of 32 Plabeled D-sequence synthetic oligonucleotide (5 0 -AG GAACCCCTAGTGATGGAG-3 0 ) in the reaction mixture. The binding reaction was allowed to proceed for 30 min at 251C. Bound complexes were separated from the unbound probe on low-ionic strength 4% polyacrylamide gels using Tris-glycine-ethylenediaminetetraacetic acid (EDTA) buffer (pH 8.5) containing 50 mM Tris-HCl, 380 mM glycine and 2 mM EDTA. Following electrophoresis, the gel was dried in vacuuo and autoradiographed with Kodak X-Omat film at À701C. These results, shown in Figure 4 , are consistent with our previous studies, 16, 17 in that 293 cells contained predominantly the Ser/Thr phosphorylated form of FKBP52, which interacted with the D-sequence probe and formed a complex (lane 2). The same complex formation was seen in mocktransfected cells (lane 3). Interestingly, however, the extent of the complex formation was significantly reduced in cell clones overexpressing PP5 (lanes 4, 5 and 6) compared with control and mock-transfected cells. As we have previously documented that only phosphorylated forms of FKBP52 form a complex with the D-sequence, and that dephosphorylated FKBP52 does not interact with D-sequence, [7] [8] [9] these EMSAs results further confirm that PP5 catalyzes the dephosphorylation FKBP52 at Ser/Thr residues, and that the decreased interaction with the D-sequence leads to a more efficient viral second-strand DNA synthesis, and consequently enhanced transduction efficiency of ssAAV vectors.
Based on these data, we have updated our previously published model of FKBP52 phosphorylation and AAV DNA second-strand synthesis and transgene expression, 7 which is shown in Figure 5 . Briefly, FKBP52, phosphorylated at Tyr residues by epidermal growth factor receptor protein tyrosine kinase, specifically binds to the D-sequence, and strongly inhibits AAV second-strand DNA synthesis. FKBP52 is dephosphorylated at Tyr residues by TC-PTP. Unphosphorylated form of FKBP52 can no longer interact efficiently with the AAV D-sequence, and has little influence on the viral second-strand DNA synthesis. FKBP2 is dephosphorylated at Ser/Thr residues by PP5, which effectively reduces the extent of its interaction with the D-sequence, which in turn, allows efficient viral second-strand DNA synthesis, thereby augmenting the transduction efficiency of AAV vectors.
It is important to note that one final piece of the puzzle -the identity of the putative cellular Ser/Thr kinase that phosophorylates FKBP52 at Ser/Thr residues -still remains elusive. However, our working hypothesis is that FKBP52 is phosphorylated at Ser/Thr residues by the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs). This hypothesis stems from the following observations: (i) Wechsler et al. 31 have documented that PP5 interacts with DNA-PKcs and specifically catalyzes its dephosphorylation; (ii) Song et al. 43, 44 have shown that DNA-PKcs negatively affects the formation of AAV AAV-mediated gene transfer W Zhao et al circular DNA intermediates and inhibits integration of the proviral genome; (iii) Zentilin et al. 45 have found that Ku86, a subunit of DNA-PK recognizes the hairpin structure of the AAV genome and associates with the viral DNA in transduced cells, and that AAV transduction is increased in Ku86-defective cells; (iv) Silverstein et al. 46 have reported that PP5 interacts with cellular heatshock protein 90 (HSP90), 47 which is phosphorylated at Ser/Thr residues; and (v) we have demonstrated that HSP90 is involved in the complex formation with FKBP52 with the AAV D-sequence. 13 The final proof of the involvement of DNA-PKcsmediated phosphorylation of FKBP52 at Ser/Thr residues must await direct experimental evidence. However, we postulate that, in accord with our previously published studies with TC-PTP, 9-11 the development of scAAV-PP5 as a helper-virus as well as PP5-transgenic mice, both currently underway, is likely to contribute to a better understanding of the underlying mechanism of recombinant AAV vector-mediated gene transfer and transgene expression in vivo. ?DNA-PKcs PP5 Figure 5 Revised model for the role of cellular FKBP52 and its phosphorylation status in AAV second-strand DNA synthesis. The ?DNA-PKcs implies the lack of direct experimental proof that FKBP52 is phosphorylated at Ser/Thr residues by DNA-PKcs. See text for details.
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